Coherus BioSciences to Divest its Ophthalmology Franchise to Sandoz for $170M Up Front
Shots:
- Coherus signs an agreement with Sandoz to divest its ophthalmology franchise which includes a lead asset Cimerli ((ranibizumab-eqrn) along with its supporting commercial infrastructure
- As per the terms of the agreement, Coherus will receive an all-cash consideration of $170M as up front payment along with an additional amount for Cimerli product inventory & subject to customary working capital adjustments at the closing date. The transaction is expected to close by H1’24
- Moreover, the divestiture also includes Coherus’ BLA for Cimerli, ophthalmology sales, select field reimbursement teams, Cimerli product inventory on hand & the access to proprietary commercial software
Ref: FORMYCON | Image: FORMYCON
Related News:- Formycon AG Reports Preliminary P-III Trial (MAGELLAN-AMD) Results FYB203, a Proposed Biosimilar to Eylea
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
